TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vascular Inflammation in Psoriasis - Extension Study
Brief Summary: VIP-E is a one-arm, open-label, 40-52 week extension study to continue or cross over subjects of the VIP study (# 814278) to active drug (adalimumab) to determine if there is sustained improvement in vascular inflammation, lipid metabolism, and inflammatory markers. VIP-E extends VIP study procedures for 40-52 weeks including questionnaires, physical exams, blood and urine samples, lab tests, one additional FDG-PET/CT scan, and adalimumab injections following FDA-approved psoriasis treatment regimen.


Options:
A: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Drug: Etanercept + Acitretin | Arm Label: Group C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acitretin | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: Etanercept + Acitretin; Assigned to Arm(s): Group B | Intervention Type: DRUG; Name: Acitretin; Assigned to Arm(s): Group C
B: Arm Label: Apremilast; Type: EXPERIMENTAL; Interventions: Drug: Apremilast, Drug: Placebo, Drug: Placebo-Apremilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Placebo-Apremilast | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Apremilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Apremilast, Placebo | Intervention Type: DRUG; Name: Placebo-Apremilast; Assigned to Arm(s): Apremilast, Placebo
C: Arm Label: UCB4940 8 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 40 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 160 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 480 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 640 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: UCB4940; Assigned to Arm(s): UCB4940 160 mg, UCB4940 40 mg, UCB4940 480 mg, UCB4940 640 mg, UCB4940 8 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Single-Arm, open-label extension trial; Type: OTHER; Interventions: Drug: Adalimumab | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Single-Arm, open-label extension trial

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vascular Inflammation in Psoriasis - Extension Study
Brief Summary: VIP-E is a one-arm, open-label, 40-52 week extension study to continue or cross over subjects of the VIP study (# 814278) to active drug (adalimumab) to determine if there is sustained improvement in vascular inflammation, lipid metabolism, and inflammatory markers. VIP-E extends VIP study procedures for 40-52 weeks including questionnaires, physical exams, blood and urine samples, lab tests, one additional FDG-PET/CT scan, and adalimumab injections following FDA-approved psoriasis treatment regimen.


Options:
A: Arm Label: Ixekizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Fumaric Acid Esters; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fumaric Acid Esters, Drug: Ixekizumab | Arm Label: Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Ixekizumab | Intervention Type: DRUG; Name: Fumaric Acid Esters; Assigned to Arm(s): Fumaric Acid Esters | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Fumaric Acid Esters, Ixekizumab, Methotrexate
B: Arm Label: Induction Single Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: Induction Monthly Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457A | Arm Label: Induction Early Loading Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457A | Arm Label: Placebo Dose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): Induction Single Dose | Intervention Type: DRUG; Name: AIN457A; Assigned to Arm(s): Induction Monthly Dose | Intervention Type: DRUG; Name: AIN457A; Assigned to Arm(s): Induction Early Loading Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Dose
C: Arm Label: 80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W); Type: EXPERIMENTAL; Interventions: Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 | Arm Label: 80 mg Ixekizumab Dosing Regimen 2 (Q4W); Type: EXPERIMENTAL; Interventions: Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 | Arm Label: 80 mg Ixekizumab Dosing Regimen 3 (Q12W); Type: EXPERIMENTAL; Interventions: Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3; Assigned to Arm(s): 80 mg Ixekizumab Dosing Regimen 2 (Q4W), 80 mg Ixekizumab Dosing Regimen 3 (Q12W), 80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Single-Arm, open-label extension trial; Type: OTHER; Interventions: Drug: Adalimumab | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Single-Arm, open-label extension trial

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vascular Inflammation in Psoriasis - Extension Study
Brief Summary: VIP-E is a one-arm, open-label, 40-52 week extension study to continue or cross over subjects of the VIP study (# 814278) to active drug (adalimumab) to determine if there is sustained improvement in vascular inflammation, lipid metabolism, and inflammatory markers. VIP-E extends VIP study procedures for 40-52 weeks including questionnaires, physical exams, blood and urine samples, lab tests, one additional FDG-PET/CT scan, and adalimumab injections following FDA-approved psoriasis treatment regimen.


Options:
A: Arm Label: Placebo (Part A); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo for risankizumab, Drug: placebo for ustekinumab | Arm Label: Ustekinumab (Part A); Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab, Drug: placebo for risankizumab | Arm Label: Risankizumab (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Drug: placebo for ustekinumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab (Part A) | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): Ustekinumab (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Placebo (Part A), Ustekinumab (Part A) | Intervention Type: DRUG; Name: placebo for ustekinumab; Assigned to Arm(s): Placebo (Part A), Risankizumab (Part A)
B: Arm Label: Single-Arm, open-label extension trial; Type: OTHER; Interventions: Drug: Adalimumab | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Single-Arm, open-label extension trial
C: Arm Label: Secukinumab; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab | Arm Label: Ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): Secukinumab | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Ustekinumab
D: Arm Label: 210 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 210 mg brodalumab | Arm Label: 140 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 140 mg brodalumab | Arm Label: ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Intervention Type: DRUG; Name: 210 mg brodalumab; Assigned to Arm(s): 210 mg brodalumab, Placebo | Intervention Type: DRUG; Name: 140 mg brodalumab; Assigned to Arm(s): 140 mg brodalumab | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): ustekinumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The PREMOD Trial: A Randomized Controlled Trial of Umbilical Cord Milking vs. Delayed Cord Clamping in Premature Infants
Brief Summary: Premature babies can be very sick and have bleeding in the brain. Giving babies more blood before cutting the umbilical cord by delayed cord clamping or umbilical cord milking has been shown to reduce the risk of bleeding in the brain. This may be related to improving perfusion to the brain. However, some studies suggest that delayed cord clamping may not increase hemoglobin or blood volume in babies delivered by cesarean section. Milking the umbilical cord may give more blood in babies delivered by Cesarean Section may improve perfusion and reduce bleeding in the brain.


Options:
A: Arm Label: Umbilical Cord Milking; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Umbilical Cord Milking | Arm Label: Delayed Cord Clamping; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Delayed Cord Clamping | Intervention Type: PROCEDURE; Name: Umbilical Cord Milking; Assigned to Arm(s): Umbilical Cord Milking | Intervention Type: PROCEDURE; Name: Delayed Cord Clamping; Assigned to Arm(s): Delayed Cord Clamping
B: Arm Label: Early cord clamping (ECC); Type: OTHER; Interventions: Procedure: Early (≤30 seconds) cord clamping | Arm Label: Delayed cord clamping (DCC); Type: OTHER; Interventions: Procedure: Delayed (≤180 seconds) cord clamping | Intervention Type: PROCEDURE; Name: Early (≤30 seconds) cord clamping; Assigned to Arm(s): Early cord clamping (ECC) | Intervention Type: PROCEDURE; Name: Delayed (≤180 seconds) cord clamping; Assigned to Arm(s): Delayed cord clamping (DCC)
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Procedure: Delayed Cord Clamping | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Immediate Cord Clamping | Intervention Type: PROCEDURE; Name: Delayed Cord Clamping; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Immediate Cord Clamping; Assigned to Arm(s): B
D: Arm Label: Early umbilical cord clamping (control); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Delayed umbilical cord clamping; Type: EXPERIMENTAL; Interventions: Procedure: Delayed umbilical cord clamping | Intervention Type: PROCEDURE; Name: Delayed umbilical cord clamping; Assigned to Arm(s): Delayed umbilical cord clamping

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of Early Treatment With IgM-enriched IVIG on Critical Illness Polyneuropathy and/or Myopathy in Patients With Multiple Organ Failure and SIRS/Sepsis: A Prospective, Randomized, Placebo-controlled, Double-blinded Trial
Brief Summary: Critical illness polyneuropathy and/or myopathy (CIPNM) is a severe complication of critical illness. Retrospective data suggest that early application of IgM-enriched intravenous immunoglobulin (IVIG) may prevent or mitigate CIPNM. Therefore, the primary objective was to assess the effect of early IgM-enriched IVIG versus placebo to mitigate CIPNM in a prospective setting.


Options:
A: Arm Label: IgM-enriched Intravenous Immunoglobulins; Type: ACTIVE_COMPARATOR; Interventions: Drug: IgM-enriched Intravenous Immunoglobulins | Arm Label: Human Albumin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Human Albumin | Intervention Type: DRUG; Name: IgM-enriched Intravenous Immunoglobulins; Assigned to Arm(s): IgM-enriched Intravenous Immunoglobulins | Intervention Type: DRUG; Name: Human Albumin; Assigned to Arm(s): Human Albumin
B: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: cisatracurium, Drug: Cisatracurium besilate | Intervention Type: DRUG; Name: cisatracurium; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Cisatracurium besilate; Assigned to Arm(s): B
C: Arm Label: Intensive Insulin therapy; Type: EXPERIMENTAL; Interventions: Other: Intensive Insulin Therapy | Arm Label: Conventional Therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional Insulin therapy | Intervention Type: OTHER; Name: Intensive Insulin Therapy; Assigned to Arm(s): Intensive Insulin therapy | Intervention Type: OTHER; Name: Conventional Insulin therapy; Assigned to Arm(s): Conventional Therapy
D: Intervention Type: DRUG; Name: intensive insulin therapy to maintain normoglycemia; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BIOTRONIK's - First in Men Study of the Passeo-18 LUX Drug Releasing PTA Balloon Catheter vs. the Uncoated Passeo 18 Balloon Catheter in Subjects Requiring Revascularization of Infrapopliteal Arteries (BIOLUX P-II).
Brief Summary: A prospective, multicentric, randomized controlled trial to assess the safety and performance of the Passeo-18 Lux Paclitaxel releasing PTA balloon catheter versus the uncoated Passeo 18 PTA balloon catheter for the treatment of stenosis, restenosis or occlusion of the infrapopliteal arteries.


Options:
A: Arm Label: Moxy Drug Coated Balloon; Type: EXPERIMENTAL; Interventions: Device: Moxy Drug Coated Balloon | Arm Label: Standard Uncoated Angioplasty Balloon; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard Uncoated Angioplasty Balloon | Intervention Type: PROCEDURE; Name: Standard Uncoated Angioplasty Balloon; Assigned to Arm(s): Standard Uncoated Angioplasty Balloon | Intervention Type: DEVICE; Name: Moxy Drug Coated Balloon; Assigned to Arm(s): Moxy Drug Coated Balloon
B: Arm Label: Passeo-18 Lux DRB; Type: EXPERIMENTAL; Interventions: Device: Passeo-18 Lux DRB | Arm Label: Standard PTA (POBA); Type: ACTIVE_COMPARATOR; Interventions: Device: Standard PTA (POBA) | Intervention Type: DEVICE; Name: Passeo-18 Lux DRB; Assigned to Arm(s): Passeo-18 Lux DRB | Intervention Type: DEVICE; Name: Standard PTA (POBA); Assigned to Arm(s): Standard PTA (POBA)
C: Arm Label: DEB; Type: N/A; Interventions: Device: DEB | Arm Label: conventional PTA; Type: N/A; Interventions: Device: POBA | Intervention Type: DEVICE; Name: DEB; Assigned to Arm(s): DEB | Intervention Type: DEVICE; Name: POBA; Assigned to Arm(s): conventional PTA
D: Arm Label: Drug-Coated Balloon (DCB); Type: EXPERIMENTAL; Interventions: Device: Drug-Coated Balloon (DCB) | Arm Label: Standard PTA; Type: ACTIVE_COMPARATOR; Interventions: Device: PTA Balloon: Balloon Angioplasty | Intervention Type: DEVICE; Name: Drug-Coated Balloon (DCB); Assigned to Arm(s): Drug-Coated Balloon (DCB) | Intervention Type: DEVICE; Name: PTA Balloon: Balloon Angioplasty; Assigned to Arm(s): Standard PTA

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mirtazapine for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomized, Double-blind, Placebo-controlled Study
Brief Summary: The purpose of this study is to determine whether mirtazapine is effective in the treatment of sleep disorders in Alzheimers disease.


Options:
A: Arm Label: Mirtazapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mirtazapine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DRUG; Name: Mirtazapine; Assigned to Arm(s): Mirtazapine
B: Arm Label: Trazodone; Type: EXPERIMENTAL; Interventions: Drug: Trazodone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Trazodone; Assigned to Arm(s): Trazodone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Suvorexant; Type: EXPERIMENTAL; Interventions: Drug: Suvorexant | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Suvorexant; Assigned to Arm(s): Suvorexant | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Therapy light room; Type: ACTIVE_COMPARATOR; Interventions: Other: Therapy light room | Arm Label: Standard light; Type: PLACEBO_COMPARATOR; Interventions: Other: Standard light | Intervention Type: OTHER; Name: Therapy light room; Assigned to Arm(s): Therapy light room | Intervention Type: OTHER; Name: Standard light; Assigned to Arm(s): Standard light

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Effectiveness of Adding Weight Control to Smoking Cessation Quitlines
Brief Summary: This randomized controlled trial compares the effectiveness for both smoking cessation and weight control of two alternative combined interventions offered via telephone quitline, as compared to standard of care quitline treatment addressing cessation alone. The interventions to be compared are cessation treatment alone versus cessation treatment combined with weight control treatment added either simultaneously or sequentially.


Options:
A: Arm Label: Incentives; Type: EXPERIMENTAL; Interventions: Behavioral: NH Medicaid Incentives Program | Arm Label: No Incentives; Type: EXPERIMENTAL; Interventions: Behavioral: NH Medicaid Incentives Program | Intervention Type: BEHAVIORAL; Name: NH Medicaid Incentives Program; Assigned to Arm(s): Incentives, No Incentives
B: Intervention Type: BEHAVIORAL; Name: Self-Help Intervention Program-High Blood Pressure; Assigned to Arm(s): N/A
C: Arm Label: PRO+NRT+TC; Type: EXPERIMENTAL; Interventions: Other: proactive outreach (PRO), Other: telephone counseling (TC), Other: Nicotine replacement therapy (NRT) | Arm Label: Usual Care (UC); Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care (UC) | Intervention Type: OTHER; Name: proactive outreach (PRO); Assigned to Arm(s): PRO+NRT+TC | Intervention Type: OTHER; Name: telephone counseling (TC); Assigned to Arm(s): PRO+NRT+TC | Intervention Type: OTHER; Name: Nicotine replacement therapy (NRT); Assigned to Arm(s): PRO+NRT+TC | Intervention Type: OTHER; Name: Usual care (UC); Assigned to Arm(s): Usual Care (UC)
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smoking cessation | Arm Label: Simultaneous; Type: EXPERIMENTAL; Interventions: Behavioral: Weight gain prevention and smoking cessation | Arm Label: Sequential; Type: EXPERIMENTAL; Interventions: Behavioral: Weight gain prevention and smoking cessation | Intervention Type: BEHAVIORAL; Name: Weight gain prevention and smoking cessation; Assigned to Arm(s): Sequential, Simultaneous | Intervention Type: BEHAVIORAL; Name: Smoking cessation; Assigned to Arm(s): Control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Effectiveness of Adding Weight Control to Smoking Cessation Quitlines
Brief Summary: This randomized controlled trial compares the effectiveness for both smoking cessation and weight control of two alternative combined interventions offered via telephone quitline, as compared to standard of care quitline treatment addressing cessation alone. The interventions to be compared are cessation treatment alone versus cessation treatment combined with weight control treatment added either simultaneously or sequentially.


Options:
A: Arm Label: placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline tartrate | Arm Label: bupropion; Type: EXPERIMENTAL; Interventions: Drug: bupropion hydrochloride | Arm Label: Nicotine Replacement Therapy Patch; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Replacement Therapy Patch | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline tartrate; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: bupropion hydrochloride; Assigned to Arm(s): bupropion | Intervention Type: DRUG; Name: Nicotine Replacement Therapy Patch; Assigned to Arm(s): Nicotine Replacement Therapy Patch
B: Arm Label: Naltrexone and Bupropion; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone, Drug: Bupropion | Arm Label: Placebo Naltrexone and Bupropion; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Naltrexone, Drug: Placebo Bupropion | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): Naltrexone and Bupropion | Intervention Type: DRUG; Name: Placebo Naltrexone; Assigned to Arm(s): Placebo Naltrexone and Bupropion | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Naltrexone and Bupropion | Intervention Type: DRUG; Name: Placebo Bupropion; Assigned to Arm(s): Placebo Naltrexone and Bupropion
C: Arm Label: varenicline with counselling; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo with counselling; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline with counselling | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo with counselling
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smoking cessation | Arm Label: Simultaneous; Type: EXPERIMENTAL; Interventions: Behavioral: Weight gain prevention and smoking cessation | Arm Label: Sequential; Type: EXPERIMENTAL; Interventions: Behavioral: Weight gain prevention and smoking cessation | Intervention Type: BEHAVIORAL; Name: Weight gain prevention and smoking cessation; Assigned to Arm(s): Sequential, Simultaneous | Intervention Type: BEHAVIORAL; Name: Smoking cessation; Assigned to Arm(s): Control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Proyecto Mama: Lifestyle Intervention in Overweight and Obese Pregnant Hispanic Women
Brief Summary: The overall goal of this randomized controlled trial is to test the efficacy of a culturally and linguistically modified, individually tailored lifestyle intervention to reduce excess gestational weight gain (GWG), increase postpartum weight loss, and improve maternal metabolic status among overweight/obese Hispanic women.


Options:
A: Arm Label: Nutritional counseling + exercise groups; Type: EXPERIMENTAL; Interventions: Behavioral: Nutritional counseling + exercise groups | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Nutritional counseling + exercise groups; Assigned to Arm(s): Nutritional counseling + exercise groups
B: Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Health and Wellness; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention
C: Arm Label: Parents As Teachers + Lifestyle Int.; Type: EXPERIMENTAL; Interventions: Behavioral: Parents As Teachers Plus (PAT+) | Arm Label: Standard Parents as Teachers (PAT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Parents As Teachers (PAT) | Intervention Type: BEHAVIORAL; Name: Standard Parents As Teachers (PAT); Assigned to Arm(s): Standard Parents as Teachers (PAT) | Intervention Type: BEHAVIORAL; Name: Parents As Teachers Plus (PAT+); Assigned to Arm(s): Parents As Teachers + Lifestyle Int.
D: Arm Label: Lifestyle and nutrition control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lifestyle intervention group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle intervention group | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention group; Assigned to Arm(s): Lifestyle intervention group

Answer: B